Delivering an essential metal to the bloodstream is a formulation problem as well as a nutritional one. Iron saccharate, also called iron sucrose, illustrates the difference. The identity associated with CAS 8047-67-4 is not adequately represented by imagining one iron atom attached to one sugar molecule. Pharmaceutical iron sucrose is a complex containing polynuclear iron(III)-hydroxide associated with sucrose. The structure and behavior of that assembly help explain why it belongs to the history of intravenous iron preparations.
The naming can be misleading outside its pharmaceutical context. Sucrose is a carbohydrate, whereas saccharic acid is an oxidized sugar acid; their names do not make their iron compounds interchangeable. The FDA substance record links iron saccharate, iron sucrose and ferric hydroxide sucrose complex under the same ingredient identity. That connection is more useful than an isolated catalog formula that might depict a different iron-carbohydrate salt. For this material, composition and physical organization matter alongside the familiar elemental symbol Fe.
The clinical objective is to provide iron that can enter the body's normal pathways for storage and red-cell production. Iron deficiency can arise when intake or absorption does not meet demand, when blood is lost, or in disease settings where iron handling is disturbed. Oral preparations are useful in many circumstances, but intravenous formulations provide another route when the clinical situation calls for it. Bypassing intestinal absorption does not remove the need to control how the metal is presented and administered.
Iron sucrose has a longer clinical history than its United States approval date suggests. A 2020 review traces clinical use to 1949, while the prescribing information for Venofer records initial US approval in 2000. The distinction separates the development of a treatment approach from the approval history of a particular product in one jurisdiction. It also shows how an established material can continue to generate questions about its structure, handling and clinical performance decades after introduction.
The assembly is described as a nanomedicine in the review literature. This does not mean that nanoscale size alone is its therapeutic purpose. A small iron-containing core and its carbohydrate-associated environment form a system whose properties are not captured by a simple low-molecular-weight formula. Distribution of particle characteristics, stability and release behavior can influence how a preparation interacts with biological processes. Consequently, comparison of two products requires more than matching their total iron content or applying the same general ingredient name.
This distinction is reflected in pharmaceutical description and quality control. The prescribed dose is expressed in elemental iron, while the administered material is the complete iron-sucrose formulation. Total metal content answers how much iron is supplied; it does not by itself establish that two preparations are physicochemically identical. The same principle applies to research samples: a material labeled iron saccharate is not automatically equivalent to a sterile, controlled medicinal product.
This is also why the carbohydrate cannot be treated as a decorative part of the name. The iron-containing assembly, its surrounding medium and its manufacturing controls all contribute to defining the administered preparation.
In current US prescribing information, Venofer is indicated for iron-deficiency anemia in patients with chronic kidney disease. Administration requires medical monitoring because serious hypersensitivity reactions and hypotension can occur, and excessive iron replacement can produce iron overload. These limitations are part of the compound's applied chemistry, not an unrelated qualification. Iron saccharate's importance lies in transforming a reactive essential element into a usable delivery system, where the relationship between metal, carbohydrate and formulation is central to its function.
References:
1. FDA GSRS. Iron sucrose; UNII FZ7NYF5N8L; CAS 8047-67-4. https://precision.fda.gov/uniisearch/srs/unii/fz7nyf5n8l
2. Macdougall IC et al. Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. Adv Ther. 2020;37:1960-2002. DOI: 10.1007/s12325-020-01323-z. https://doi.org/10.1007/s12325-020-01323-z
3. DailyMed. VENOFER (iron sucrose) injection. Prescribing information, sections 1, 5, 11 and 12. Accessed 2026-10-20. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a
|
chemBlink Chemical Story